

# THE ROLE PHARMACEUTICAL MARKET ACCESS FOR PATIENTS

LILI MUSNELINA

JAKARTA, 12 JANUARI 2016

#### **DEFINITION**

### Health (WHO):

a state of complete physical, mental and social well being nor merely the absence of disease or infirmity

### **DEFINITION**

#### Market access:

a process that ensure all appropriate patients have rapid and continues access to the product at the right price

### **DEFINITION**

Patient can be considered as the centre for any healthcare system

#### MARKET ACCESS

 Generally, market access is perceived as a function that is confined to pricing and reimbursement activities

 However, in reality, it is multidisciplinary field that includes aspects from various other business functions, such as managing channels, stakeholders and key opinion leaders

# MARKET ACCESS: FACTS

- Market access stakeholders:
  - -Payers
  - Patients
  - Pharmacies
  - Advocacy group
  - Physicians
  - Government
  - Regulatory

### MARKET ACCESS: FACTS

 Current industry commercial models are inadequate assessing opportunities in emerging economies where disease and market data are highly limited

### MARKET ACCESS: FACTS

- Biopharmaceutical companies face multiple external pressures:
  - shareholders demand and profitable company
  - government, nongovernment third parties and public expert commitment to improving health

#### WHAT PATIENTS RIGHT?

- Get immediate to innovative medicine:
  - Can live longer
  - Improve their living conditions

#### WHAT PATIENTS RIGHT?

- Get Access treatment which:
  - Limited side effects
  - Offer convenience or the ability to continue with normal everyday activities
  - Reduce complications

#### PATIENT SATISFACTION

- Patient are becoming better informed
- Involve patients for making improvements
- Patient satisfaction is not static but dynamic

#### PATIENT SATISFACTION

- Health care is generally becoming competitive
- Providers must not only maintain high clinical
- Standards but also service that satisfies the patients

#### PATIENT BENEFIT

 Access to drugs cannot depend on the decisions of private companies but is also a government responsibility

#### MARKET ACCESS AND PATIENTS BENEFIT

 Partnering with patients in the development and lifecycle of medicines

Early market access

- Purpose of medicines: improve patients live
- Patients:
  - ensure that patient needs and priorities are identified and met
  - provide better quality of life

• Pharmaceutical companies:

provide benefit patients, it will bring enough profit

#### • Government:

- develop rules for drugs development easier on safety
- support patient advocacy groups financially, less dependent on the pharmaceutical companies

- Drug development:
  - improve trial conduct and lead to more focused
  - economically viable clinical trials

- Launch and Beyond:
  - systemic patient involvement can also improve the ongoing benefit risk assessment
  - ensure public funds prioritize medicines of value to patients

## **THANK YOU**